Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.85 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.70 |
| ▸ | CALCA | P06881 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479542 | 1.00 | CALCRL (0.85) | CALCRLRAMP1CALCA | |
| SCHEMBL12657930 | 0.91 | CALCRL (0.87) | CALCRLRAMP1CALCA | |
| SCHEMBL12657934 | 0.89 | CALCRL (0.82) | CALCRLRAMP1CALCA | |
| SCHEMBL2526810 | 0.89 | CALCRL (0.82) | CALCRLRAMP1CALCA | |
| SCHEMBL4753444 | 0.89 | CALCRL (0.82) | CALCRLRAMP1CALCA | |
| SCHEMBL13288892 | 0.89 | CALCRL (0.82) | CALCRLRAMP1CALCA | |
| SCHEMBL2526808 | 0.89 | CALCRL (0.82) | CALCRLRAMP1CALCA | |
| SCHEMBL12657933 | 0.87 | CALCRL (0.78) | CALCRLRAMP1CALCA | |
| SCHEMBL1435277 | 0.87 | CALCRL (0.79) | CALCRLRAMP1CALCA | |
| SCHEMBL13288890 | 0.86 | CALCRL (0.77) | CALCRLRAMP1CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039460-B2 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headache; compounds based on 6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine or 6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039460-B2 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headache; compounds based on 6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine or 6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039460-B2 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headache; compounds based on 6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine or 6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1802372-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-1802372-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7732438-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732438-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732438-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1802637-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1802637-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20080113966-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-15 | — | — | US | disclosed |
| US-20080113966-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-15 | — | — | US | disclosed |
| US-20080113966-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-15 | — | — | US | disclosed |
| US-20070287697-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
| US-20070287697-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
| US-20070287697-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113966-A1 | Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | CALCRL 4/4885RAMP1 116/4885CALCA 18/4885 |
| US-20070287697-A1 | Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | CALCRL 4/4885RAMP1 70/4885CALCA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.